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Abstract: Peptide gH625, derived from glycoprotein H of herpes simplex virus type 1, can 
enter cells efficiently and deliver a cargo. Nanoparticles armed with gH625 are able to cross an 
in vitro model of the blood–brain barrier (BBB). In the present study, in vitro experiments were 
performed to investigate whether gH625 can enter and accumulate in neuron and astrocyte cell 
lines. The ability of gH625 to cross the BBB in vivo was also evaluated. gH625 was administered 
in vivo to rats and its presence in the liver and in the brain was detected. Within 3.5 hours of 
intravenous administration, gH625 can be found beyond the BBB in proximity to cell neurites. 
gH625 has no toxic effects in vivo, since it does not affect the maximal oxidative capacity of 
the brain or the mitochondrial respiration rate. Our data suggest that gH625, with its ability to 
cross the BBB, represents a novel nanocarrier system for drug delivery to the central nervous 
system. These results open up new possibilities for direct delivery of drugs into patients in the 
field of theranostics and might address the treatment of several human diseases.
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Introduction
Advances in molecular biology, nanotechnology, and pharmaceutical chemistry have 
led to the rapid evolving interdisciplinary field of nanomedicine, with the production of 
several new classes of imaging agents and highly potent drugs. One of the key topics in 
nanomedicine is targeted delivery of drugs to specific sites of disease in the body. Drugs 
are often characterized by physicochemical and/or biological features that make their 
use not ideal in humans; however, nanosized delivery systems (liposomes, micelles, and 
polymeric systems) can circumvent these problems by improving the therapeutic index.1,2 
Apart from a few exceptions, nanocarriers have met with moderate success, mainly because 
of their behavior in vivo.3 Free diffusion of circulating molecules from the blood into 
the brain is made difficult by the presence of the blood–brain barrier (BBB), which is a 
complex physiological checkpoint in the central nervous system, preventing passage of 
both beneficial drugs and potentially toxic molecules.4,5 For this reason, many diseases 
affecting the brain still cannot be treated effectively. Therefore, development of novel 
systems that can significantly enhance the delivery of therapeutic agents across the BBB 
represents a fundamental challenge for the treatment of a number of brain diseases.6,7
Cationic cell-penetrating peptides are a group of short peptides able to cross the 
membrane bilayer using a mechanism mediated by endocytosis, and are well suited for 
development as drug delivery vehicles to penetrate the BBB. Their advantages as deliv-
ery enhancers are their relatively small molecular weight, ease of synthesis, relatively 
low cytotoxicity and immunogenicity, and degradation in vivo to naturally occurring 
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compounds.8 The mechanism of their uptake is still debated, 
although endocytosis is believed to be the main pathway 
involved;9 thus, the cargo is trapped in endosomes, eventu-
ally ending in lysosomes, and its intracellular bioavailability 
is decreased. To be able to avoid the endocytic pathway, it is 
important to design new molecules operating under different 
mechanisms of uptake. The new challenge of recent research is 
the use of hydrophobic peptides; these have a key role in sev-
eral processes involving temporary membrane destabilization 
and subsequent reorganization, such as crossing of biological 
membranes and promoting lipid membrane-reorganizing pro-
cesses (fusion or pore formation).10,11 The intrinsic ability of 
virus-derived peptides to induce membrane perturbation may 
be useful in the design of delivery vehicles.12–14
The peptide gH625, previously identified as a membrane-
perturbing domain in glycoprotein H (gH) of herpes simplex 
virus 1, has been demonstrated to be able to traverse the 
membrane bilayer.15 Further, gH625 has been used extensively 
for vector-mediated strategies that enable passage of a large 
variety of small molecules as well as proteins across cell 
membranes in vitro.16–20 Conjugation of gH625 to the surface of 
nanoparticles also enhances their transport across the BBB, as 
previously demonstrated in an in vitro model of the BBB.19
Whether or not multifunctional nanodevices, designed 
and tested in vitro, work properly in vivo in a mammalian 
host is still not fully understood. In vivo studies are neces-
sary to address this issue, thus validating design strategies 
and facilitating optimization and further functionalization. 
Although numerous studies have shown that gH625 is an 
efficient carrier for bioactive cargoes in vitro,21 these results 
do not guarantee that gH625 can be developed into a useful 
pharmaceutical delivery platform.
The aim of the current study was to evaluate whether 
gH625 can enter into brain cells in vitro and whether it crosses 
the BBB when administered to rats in vivo. We investigated 
cell viability and mitochondrial functionality/maximal oxida-
tive capacity on exposure of neuroblastoma and glioblastoma-
astrocytoma cell lines to gH625. The passage of gH625 across 
the BBB in vivo was evaluated after its intravenous administra-
tion in rats. Our results may have importance for the treatment 
of brain diseases and tracking of nanosystems in vivo, bringing 
us a step closer to having available a nanocarrier for treatment 
as well as monitoring of brain-related disorders.
Materials and methods
Materials
Dulbecco’s modified Eagle’s medium and fetal bovine serum 
were purchased from BioWhittaker (Verseviers, Belgium). 
L-glutamine, penicillin, and streptomycin were from Gibco 
(Life Technologies, monza, Italy). Cell culture flasks (25 cm2), 
96-well cell culture plates, and sterile pipettes were obtained from 
Becton-Dickinson (milan, Italy). mTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide] was from Sigma-Aldrich 
(St Louis, mO, USA). Cytochrome c, succinate rotenone, 
malonate, sodium ascorbate, and N,N,N’,N’-tetramethyl-p-
phenylenediamine were also from Sigma-Aldrich.
Peptide synthesis
The gH625 peptide (H
2
N-HGLASTLTRWAHYNALIRAF-
GGG-CONH
2
; molecular weight 2,461 Da) was synthesized 
using the standard solid-phase-9-fluorenylmethoxycarbonyl 
(Fmoc) method as previously reported.13 The peptide was 
obtained with good yields (30%–40%). Labeling was 
performed on resin-bound peptides as previously reported 
by Rapaport and Shai.22 Specifically, 30–70 mg of resin-
bound peptide (10–25 µmol) was treated with piperidine in 
N,N-dimethylformamide to remove the Fmoc-protecting 
group of the N-terminal amino acid. The resin-bound peptide 
was then reacted with NBD-Cl (4-chloro-7-nitrobenz-2-oxa-
1,3-diazole) in N,N-dimethylformamide (3–4 equivalents). 
The resin-bound peptides were washed thoroughly after 
24 hours with methylene chloride. The peptides were cleaved 
from the resin and purified as previously reported for non-
labeled peptides. A major product was obtained with an 
NBD moiety attached to the peptide’s N-terminal amino 
group. The identity of this compound was confirmed by 
liquid chromatography-mass spectrometry. The peptide was 
dissolved in phosphate-buffered saline as vehicle.
cell culture
The human neuroblastoma cell line (SH-SY5Y) was obtained 
from the American Type Culture Collection (Rockville, mD, 
USA). The human glioblastoma-astrocytoma cell line (U-87 
mG) was kindly provided by Pasquale Barba (Institute of Genet-
ics and Biophysics, Naples, Italy). Both cell lines (500,000 
cells) were seeded in 50 mL tissue culture flasks (25 cm2 
surface), and grown in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal bovine serum, 2 mm 
L-glutamine, 100 U/mL penicillin, and 100 µg/mL strep-
tomycin (complete medium) at 37°C under a humidified 
atmosphere of 5% CO
2
 in air. The medium was changed 
twice a week, and cells were subcultivated when confluent.
MTT assay for analysis of cell viability
The mTT assay was performed to evaluate the viability 
and metabolic state of the cells. mTT is taken up by cells 
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and transformed into formazan by mitochondrial succinate 
dehydrogenase. Accumulation of formazan directly reflects 
the activity of the mitochondria, an indirect measurement 
of cell viability. In detail, in order to evaluate the effect 
of gH625 on the viability of neurons and astrocytes, SH-
SY5Y (at a density of 8,000 cells/well) and U-87 mG (at 
a density of 5,000 cells/well) were seeded into 96 well-
plates and incubated with increasing concentrations of 
peptide (0.5, 1, 5, 10, and 15 µm) for 20 hours. As  negative 
controls, we used the phosphate-buffered saline. In par-
ticular, the same volumes (corresponding to the added 
peptide solutions) of the phosphate-buffered saline were 
added to the control wells; no significant differences were 
found. As a positive control, we added 400 or 800 µm 
of H
2
O
2
, which is known to induce cell death in these cell 
lines. At the end of each incubation, the medium was removed 
and the cells were incubated with mTT solution (0.5 mg/mL) 
for 3 hours at 37°C. The medium with mTT solution was 
then gently removed, and the formazan crystals were dis-
solved in isopropanol with, 0.1 m HCl. The optical density 
was detected with a microplate reader at 590 nm.
Fluorescence analysis in vitro
The SH-SY5Y and U-87 mG cell lines were then used to 
assess uptake of gH625. Cells were seeded at a density of 
60,000/well on four-well chamber slides (x-well; Sarstedt 
AG & Co, Nümbrecht, Germany). Each well was treated 
with gH625 1 or 5 µm for 2 hours. The cells were then 
fixed in ice-cold methanol for 10 minutes and mounted 
with a coverslip in glycerol/phosphate-buffered saline 
1:1. The cell nuclei were counterstained with DAPI (4′-6 
diamidino-2-phenylindole) dilactate (Life Technologies). 
The slides were then analyzed using an epifluorescent micro-
scope (Axioskop; Zeiss, Oberkochen, Germany), mounting 
the 40× objective with a numerical aperture of 1.3. Images 
were acquired using an AxioCam mR c5 (Zeiss) with dif-
ferential interference contrast, a fluorescein isothiocyanate 
channel (λ
ex
 488 nm; λ
em
 515 nm) and a DAPI channel (λ
ex
 
350 nm; λ
em
 461 nm).
Spectrofluorimetric analysis in vitro
To evaluate the percentage of internalized peptide, gH625 was 
administered at 1 or 5 µm for 2 hours to SH-SY5Y and U-87 
mG cells previously seeded (5×104 cell/well) for 20 hours 
in a white-bottomed 96-multiwell plate without serum, 
suitable for spectrofluorimetric analysis. After incubation, 
the cells were rinsed twice with phosphate-buffered saline 
for 5 minutes and then lysed with 200 µL/well of lysis 
buffer in phosphate-buffered saline (Tris-HCl 10 mm, 
ethylenediaminetetraacetic acid 5 mm, NaCl 200 mm, 
0.2% sodium dodecyl sulfate, proteinase K 100 µg/mL) 
in order to release the internalized gH625. The cell lysate 
was filtered through a 0.45 µm nylon membrane filter and 
transferred to new wells. The plates were analyzed with 
an Infinite 200 m spectrofluorimeter (Tecan, männedorf, 
Switzerland) equipped with a fluorescence filter (λ
ex
 485 nm; 
λ
em
 560 nm). The standard curve (R²=0.965) was obtained 
with different concentrations of gH625, ie, 0.625 µm, 
1.25 µm, 2.5 µm, and 5 µm (data not shown) in order to 
obtain the accurate concentration of internalized peptide. 
Spectrofluorimetric assays were performed in biological and 
technical triplicates.
animals
male Wistar rats (250–300 g) living in a temperature-
controlled room at 24°C were kept, one per cage, under an 
artificial lighting regime of 12 hours light and 12 hours dark-
ness. A commercial mash was available ad libitum and the 
animals had free access to water. The study was carried out 
in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments at the University 
of Napoli Federico II (Permit 2012/000180). All efforts were 
made to minimize suffering. The rats were divided in two 
groups, each consisting of three rats: one group received a 
single intravenous administration of vehicle and the other 
group received a single intravenous administration of gH625-
NBD at a dose of 40 µg/100 g body weight or vehicle. The 
rats were anesthetized by intraperitoneal administration of 
Zoletil® 40 mg/100 g and then euthanized by decapitation 
3.5 hours after administration of gH625-NBD. The liver 
and brain were rapidly dissected sagittally and divided in 
two symmetrical parts. One part was immediately processed 
for preparation of homogenate and the other was used for 
histological analysis.
stability of gh625 in serum
For the plasma stability assay, 0.15 mg of gH625 was added 
to 200 µL of fresh rat serum (25% v/v in phosphate-buffered 
saline) in a microvial and the mixture was incubated at 37°C. 
Aliquots (25 µL) were taken at 0, 0.5, 1, 2, 2.5, 3, and 3.5 hours, 
and quenched by adding 25 µL of a 7 m urea solution at 
95°C for 2 minutes. The proteins were precipitated with 
50 µL of trichloroacetic acid (10% v/v) and centrifuged at 
13,400 rpm for 15 minutes. The samples (8 µg) withdrawn 
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were analyzed by high-performance liquid chromatography 
on a Kinetex 5 µ C18 100 Å 150×4.60 mm, using a linear 
gradient of 10% to 40% B (acetonitrile, 0.1% trifluoroacetic 
acid) in A (H
2
O, 0.1% trifluoroacetic acid) over 5 minutes, 
followed by a linear gradient of 40% to 80% B in A over 
20 minutes (1.0 mL per minute).
Preparation of tissue homogenates
To evaluate the mitochondrial respiration rate and cyto-
chrome oxidase activity, brain and liver fragments were 
gently homogenized an isolation medium consist ing of 220 
mm mannitol, 70 mm sucrose, 20 mm Tris-HCl, 1 mm ethyl-
enediaminetetraacetic acid, 5 mm ethylene glycol tetraacetic 
acid and bovine serum albumin 1% (pH 7.4) with a Potter-
Elvehjem homogenizer (dilution 1:5 weight/volume). The 
homogenates were left on ice until detection of cytochrome 
oxidase activity or mitochondrial respiration rate.
Fluorescence histological analysis ex vivo
As soon as the brains and livers were dissected, they were 
fixed in Bouin’s fluid (71% picric acid, 5% acetic acid, 
24% formaldehyde) for 24 hours and embedded in paraffin 
wax (Carlo Erba, milan, Italy). Sagittal 10 µm brain sections 
and 7 µm sections of liver were treated with 70% ethanol 
supplemented with 0.1% Sudan Black B for 20 minutes to 
minimize autofluorescence of tissues. The slides were then 
washed three times for 5 minutes with Tris-buffered saline 
containing 0.02% Tween 20 to remove the excess Sudan 
Black B.23,24 Sections were then stained with hemallum to 
evaluate tissue morphology. After dehydration, the sections 
were mounted with DPX mountant (Sigma-Aldrich). Images 
were acquired using the AxioCam mR c5 in bright field with 
a 488 nm ex/515 nm em filter. Images were then analyzed 
using ImageJ 1.48 software.11
Immunofluorescence analysis
Brain sections were dewaxed and hydrated. Antigen unmask-
ing was performed with citrate buffer (pH 6.0) twice for 
10 minutes in a microwave at 96°C (for anti-glial fibrillary 
acidic protein [GFAP] antibody, see below). Immunolocal-
izations were carried out with primary antibodies (negative 
technical controls were obtained by omitting primary anti-
bodies) against specific endothelial protein found in areas 
with BBB (mouse monoclonal [SmI-71] anti-BBB), anti-
GFAP (Abcam, Cambridge, mA, USA), or anti-tubulin III 
to determine if the gH625-NBD signal colocalized with brain 
endothelial cells, astrocytes, or neurons, respectively. To 
visualize antibodies, two secondary antibodies were used, 
ie, Dylight 594 (Abcam) to detect anti-BBB and AlexaFluor 
594 (Life Technologies) to detect anti-GFAP and anti-tubulin 
III. Images were acquired using the AxioCam mR c5 with 
λ
ex
 488 nm/λ
em
 515 nm and λ
ex
 594 nm/λ
em
 618 nm filters. 
Five images for each experimental class were then analyzed 
with ImageJ 1.48 software or Zen 2012; the Deconvolution-
lab plugin was used to deconvolve image channels using the 
Tikhonov-miller algorithm;11 the Colocalization Colormap 
plugin was then used to evaluate the degree of correlation 
between pairs of pixels in the red and green channels, result-
ing in distribution of the values for the normalized mean 
deviation product (nmDP) and the index of correlation as 
the fraction of positively correlated pixels in the image.25 To 
evaluate the green fluorescence inside and outside the BBB 
vessels, the mean gray values of ten sections of controls 
(vehicle or gH625 without NBD; n=3) and treated animals 
(n=3) were measured within and outside the region of interest 
(ROI) of the BBB vessels. These values were then divided 
for the correspondent ROI area (µm2) and the ratio between 
the outside and inside values was indicated. The two-tailed 
unpaired t-test was used, and the values were considered 
statistically significant at P,0.01.
Detection of maximal oxidative capacity 
of cell lines and tissue homogenate
Cytochrome oxidase (COX) activity was used as a marker 
for the maximal oxidative capacity of the cells and tissues. 
In order to detect the effect of gH625 on COX activity, 
SH-SY5Y cells and U-87 mG cells were incubated with 
increasing concentrations of peptide (0.5 to 15 mm) for 
20 hours, after which the cells were lysed and homogenized 
with a Polytron® for 5 seconds. To detect cytochrome oxidase 
activity in the liver and brain homogenates, the homogenates 
were diluted 1:2 (v/v) with Lubrol (100 mg/g tissue) in order 
to unmask the enzyme activity. The homogenates were then 
left standing in ice for 30 minutes.
Cytochrome oxidase activity was determined polaro-
graphically as described by Lanni et al.26 A Clark-type oxygen 
electrode (Rank Brothers, Botttisham, UK) with an incuba-
tion chamber maintained at 37°C was used for detection of 
oxygen consumption.
Cell lysates (corresponding to 45,000 cells) were incu-
bated in 0.5 mL of reaction medium containing 30 µm 
cytochrome c, 4 µm rotenone, 0.5 mm dinitrophenol, 10 mm 
sodium malonate, and 75 mm HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) buffer at pH 7.4. COX activity 
was measured as the difference between the rate of oxygen 
consumption observed after addition of substrate (4 mm sodium 
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ascorbate with 0.3 mm N,N,N’,N’-tetramethyl-p-phenylenedi-
amine) and cell lysate, and after addition of substrate alone, in 
order to take into account the auto-oxidation of ascorbate.
The homogenate (300 µg protein) was incubated in 
1 mL of respiratory buffer (80 mm KCl, 50 mm HEPES, 
1 mm ethylene glycol tetraacetic acid, 5 mm KH
2
PO
4
, 2 mm 
mgCl
2
, and 1% bovine serum albumin, pH 7.4). Oxida-
tion of succinate, in the presence of rotenone, was used to 
detect mitochondrial respiration. To this end, the incubation 
medium was supplemented with 4 µm rotenone, and the 
homogenate was energized with 5 mm succinate in both the 
absence of adenosine diphosphate (ADP, to obtain an indica-
tion of basal respiration, in which there is no phosphorylation 
of ADP to adenosine triphosphate [ATP]) and in the pres-
ence of 200 µm ADP (to obtain indications on respiration 
in which phosphorylation of ADP is at the maximal rate 
[ADP-stimulated respiration]).
In order to be able to attribute the detected oxygen 
consumption to mitochondrial respiration or to cytochrome 
oxidase activity, 1 mm KCN (a known inhibitor of COX 
and mitochondrial respiration rate) was added to the assay 
medium. Complete inhibition of oxygen consumption by 
KCN was observed, indicating that oxygen consumption was 
due to the activity of cytochrome oxidase or to mitochondrial 
respiration rate.
Results
Peptide synthesis
The gH625 peptide was obtained with a good yield of the 
purified compound (30%–40%) and with purity higher than 
98%. The peptide sequence was also obtained labeled at the 
N-terminus with the NBD group.
effect of gh625 on viability and maximal 
oxidative capacity of sh-sY5Y or U-87 
Mg cells
The toxicity of gH625 in SH-SY5Y (neuroblastoma) cells 
and U-87 mG (astrocytoma) cells was tested using the mTT 
assay. Incubation of SH-SY5Y cells (Figure 1A) and U-87 
mG cells (Figure 1B) to gH625 at a concentration of 0.5– 
15 µm for 20 hours had no significant effect on cell viability. 
These results suggest that the peptide is not toxic to brain 
cell populations at the concentrations herein utilized. As 
a positive control, we added H
2
O
2
 (400 or 800 µm) to the 
SH-SY5Y and U-87 mG cell lines; 400 µm H
2
O
2 
induced 
death of 30% and 22% of SH-SY5Y cells and U-87 mG 
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Figure 1 effect of in vitro incubation of gh625 with sh-sY5Y cells and U-87 Mg cells on cell viability and maximal oxidative capacity.
Notes: MTT assay for sh-sY5Y cells (A) and astrocytoma U87-Mg cells (B). Indicated as zero peptide in the figure is the negative control corresponding to the cells treated 
with vehicle (the same amount in µl of the 15 µM peptide concentration). Oxidative capacity is detected as cytochrome oxidase activity in sh-sY5Y cells (C) and in U-87 
Mg cells (D). Values represent the mean ± standard error of five separate incubations.
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cells, respectively. The higher (800 µm) concentration of 
H
2
O
2 
induced a death of 45% and 52% of SH-SY5Y and 
U-87 mG cells, respectively (data not shown).
Exposure of SH-SY5Y cells to 0–15 µm gH625 for 
20 hours did not significantly affect their maximal oxidative 
capacity, as detected as cytochrome oxidase activity (Figure 1C). 
gH625 was also ineffective when incubated with U-87 mG 
cells, regardless of the concentration used (Figure 1D).
Fluorescence analysis in vitro
To confirm internalization of gH625, we examined its cellular 
uptake by fluorescence microscopy. SH-SY5Y and U-87 mG 
cells showed significant uptake of gH625 after 2 hours of 
incubation. The peptide was efficiently internalized in both 
cell lines (Figure 2E and K). NBD alone was almost unable 
to penetrate into the cells, as previously reported.16
Spectrofluorimetric analysis in vitro
A spectrofluorimetric analysis was carried out to evaluate the 
uptake of gH625 in both cell lines in a quantitative manner. 
As shown in Figure 3, the data clearly confirm the results 
obtained by microscopy. Indeed, SH-SY5Y (Figure 3A) 
and U-87 mG (Figure 3B) cells efficiently accumulated 
gH625. At low concentration (1 µm), approximately 30% of 
gH625 was internalized, while uptake was nearly complete 
(80%–90%) at a concentration of 5 µm (Figure 3).
A B C
D E F
G H I
J K L
Figure 2 In vitro uptake of 5 µM gh625.
Notes: The left column shows images acquired with differential interference contrast, the central column with the fluorescein isothiocyanate channel, and the right column 
with the 4′-6-diamidino-2-phenylindole channel. Each row represents the same field. (A–C) Negative controls for sh-sY5Y cells. (D–F) sh-sY5Y cells treated with gh625. 
(G–I) Negative controls for U-87 Mg cells. (J–L) U-87 Mg cells treated with gh625. scale bars correspond to 50 µm, except for (D–F) where they correspond to 20 µm.
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Figure 3 (A) Spectrofluorimetric analysis of SH-SY5Y cell uptake after exposure to gH625, 1 and 5 µM. (B) Spectrofluorimetric analysis of U-87 MG cell uptake after 
exposure to gh625, 1 and 5 µM.
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Figure 4 reversed-phase high-performance liquid chromatography analysis of serum stability.
Notes: representative chromatograms after several incubation times: 0 minutes (A); 90 minutes (B); 30 minutes (C); 210 minutes (D).
Abbreviation: maU, milli absorbance units.
stability of gh625 in plasma
The main obstacle to the application of peptides for drug 
delivery is their instability due to their general susceptibility 
to proteolysis in blood. Herein, we investigated the stability 
of gH625 in rat plasma. gH625 was incubated at 37°C with 
fresh rat serum. Based on reverse-phase high-performance 
liquid chromatography analyses (Figure 4), it was evident 
that gH625 starts to be degraded after 1 hour of incubation 
but the intact peptide is still present after 3.5 hours of incu-
bation (Figure 5).
Fluorescence histological analysis ex vivo
In order to perform the histological analysis, dissected brain and 
liver tissues were fixed and stained and images were acquired 
and analyzed. The fluorescence images clearly show that within 
3.5 hours of its in vivo administration, gH625 was partly taken 
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Figure 5 stability of the gh625 peptide in serum.
Notes: The remaining peptide is reported as a function of time. Values represent 
the mean ± standard error of three different experiments.
up by Kupffer cells in the liver, which are clearly distinguishable 
from hepatocytes because they possess the typical morphology 
of macrophages, and showed overfilled cytoplasm (Figure 6C 
and D). In addition, gH625 reaches the BBB and accumulates 
in the extensions of nerve cells (Figure 6G and H).
Immunofluorescence analysis
By evaluation of fluorescence levels, we demonstrated that 
gH625 passes significantly through the BBB compared to 
controls (Figure 7). Immunofluorescence demonstrated 
that gH625 accumulates in the blood vessels of the brain in 
treated rats. No signal was found in the negative control for 
the immunofluorescence technique (Figure 8A–a4). Low 
spurious fluorescent signals arose from scattered red blood 
cells in the control animals (Figure 8B–b4). There was little 
or no colocalization between gH625 and astrocytes surround-
ing the BBB, as shown by immunofluorescence and nmDP 
color images (Figure 8C–c4). There was no colocalization 
between gH625 and the BBB in the control animals (Figure 
8D–d4). more colocalization was found between gH625 and 
the endothelial BBB on immunofluorescence and nmDP 
color images (Figure 8E–e4). It is of interest that some cells 
in the cerebral cortex, which morphologically and by immu-
nofluorescence can be ascribed to neurons and their processes 
beyond the BBB were labeled for gH625, indicating the pas-
sage of gH625 through the BBB (Figure 8F–f4, Figure 9). The 
nmDP distribution values (Figure 10A and C) and the index 
of correlation (Figure 10B and D) suggest that gH625 labeling 
is correlated mainly with BBB than to astrocytes.
In vivo effect of gh625 on brain and liver 
mitochondrial respiration rates  
and maximal oxidative capacity
Following in vivo administration, gH625 did not induce 
significant changes in brain mitochondrial bioenergetic 
parameters; in fact, no changes in basal respiration (in which 
there is no synthesis of ATP), ADP-stimulated respiration 
(in which ATP synthesis proceeds at its maximal rate), and 
respiratory control ratio (index of oxidative phosphorylation 
efficiency) were detected (Figure 11). In accordance with 
these bioenergetic parameters, maximal oxidative capacity of 
the liver and brain were not affected by in vivo administration 
of gH625 (Figure 11). Overall, these data suggest that within 
3.5 hours of administration in vivo, gH625 has no toxic effect 
at the mitochondrial level in either the liver or brain.
Discussion
The BBB represents a major obstacle in the development of 
potential new therapies to treat disorders of the central ner-
vous system due to the impermeability of the cell membranes 
in this compartment to several molecules.27,28 To date, numer-
ous attempts have been made to identify and characterize 
an efficient drug delivery approach for the brain,29,30 and a 
number of strategies are now under investigation.27 These are 
mainly invasive procedures, including direct intraventricular 
administration of drugs by means of surgery and temporary 
disruption of the BBB via intracarotid infusion of hyper-
osmolar solutions; pharmacologically-based strategies that 
involve increasing the lipid solubility of the drug to facilitate 
its passage through the BBB; and physiologically-based 
strategies exploiting various carrier mechanisms.
Peptide-based carriers have attracted considerable atten-
tion in the field of targeted drug delivery due to their high 
binding affinity and specificity for targets. The presence of 
advanced technologies for peptide identification and modifi-
cation further supports the extensive application of peptides 
in the field of theranostics research.31,32
We have previously demonstrated that gH625, a 
19-residue peptide, is a membrane-perturbing domain13 that 
interacts with model membranes, contributing to their merg-
ing13 and is able to traverse the membrane bilayer and transport 
a cargo (quantum dots, liposomes, and dendrimers)16,18,20 into 
the cytoplasm and across an in vitro model of the BBB.19 
Uptake studies suggested a nonactive translocation mecha-
nism in crossing the lipid bilayer, which may vary depending 
on the cargo.15 Penetration by gH625 occurs in a rapid, con-
centration-dependent fashion that appears to be independent 
of receptors and transporters and instead is thought to target 
the lipid bilayer component of the cell membrane. Thus, in 
principle, all mammalian cell types should be susceptible to 
gH625 transduction, and indeed we have used this technology 
to transduce different cargoes into several cell types in vitro.21 
However, as with any potential pharmacological approach, it 
is necessary to translate in vitro findings to animal models to 
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Figure 6 representative histological images of the liver and brain in control rats and rats treated with 16 µM gh625.
Notes: The left column shows bright-field images and the right column shows the fluorescein isothiocyanate channel. Each row represents the same field. The scale bar 
corresponds to 50 µm. (A, B) liver section of negative control, (C, D) liver of treated animal showing Kupffer cell (arrows) overfilled with gH625, (E, F) a brain section 
from a negative control, and (G, H) brain of treated animals showing the presence of gh625 in nerve cell processes (arrows).
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Figure 7 Green fluorescence evaluation of control and gH625-treated brain slices. 
The ratio of mean fluorescence outside and inside the blood vessels of the blood–
brain barrier was calculated for at least ten slices (control animals n=3, treated 
animals n=3). **P,0.01.
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Figure 8 Representative images of brain immunofluorescence using anti-BBB and anti-GFAP in control and gH625-treated animals.
Notes: From left to right, the columns show AlexaFluor594, fluorescein isothiocyanate, DAPI, and merged and colocalization map images, respectively. For the colocalization map 
(from -1 to 1) a color scale is provided: negative indices (cold colors) represent no colocalization, while indices above 0 (hot colors) represent colocalization. (A–a4) Negative control 
(omission of primary antibody) for anti-BBB immunofluorescence in control animal (vehicle or gH625 without NBD) showing low red background and no green signal (anti-GFAP 
negative control showed the same pattern and is not shown). scale bar corresponds to 50 µm. (B–b4) Anti-GFAP immunofluorescence in a control animal. Scattered spots of low 
green signal were due to red blood cells. scale bar 50 µm. (C–c4) Anti-GFAP immunofluorescence in a gH625-treated animal showing no overlapping of red and green signal. Scale 
bar corresponds to 20 µm. (D–d4) Anti-BBB immunofluorescence in a control animal. Scattered spots of low green signal can be attributed to red blood cells. Scale bar corresponds 
to 50 µm. (E–e4) Anti-BBB immunofluorescence in a gH625-treated animal showing overlapping of red and green signal. Scale bar corresponds to 20 µm. (F–f4) anti-BBB 
immunofluorescence in a gH625-treated animal showing that the presence of gH625 beyond the BBB can be associated to nerve cell processes. Scale bar corresponds to 20 µm. 
Abbreviations: BBB, blood–brain barrier; GFAP, glial fibrillary acidic protein; NBD, 7-nitrobenz-2-oxa-1,3-diazole-4-yl; DAPI, 4,6-diamidino-2-phenylindole; nMDP, 
normalized mean deviation product.
determine whether gH625 is able to deliver molecules into 
cells of entire organisms and to keep track of the whole bio-
logical picture and the complex nano-biological interactions 
before any potential application.
Other peptides have also been proposed as drug delivery 
systems. It was demonstrated that transactivator of transcrip-
tion (TAT) is able to enter tissues in vivo in mice,33 and an 
antennapedia-homeodomain-derived peptide (ANTP) was 
able to activate endogenous T-cells in mice.34 These pep-
tides are highly positively charged, and absorptive-mediated 
transcytosis has been proposed as the mechanism for their 
transport across the BBB. A bradykinin analog was also able 
to increase the penetration of small molecules by transient 
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Figure 9 Immunofluorescence for anti-tubulin III on cerebral cortex sections from gH625-NBD-treated animals.
Notes: (A) Neurons appear largely without labeling for gh625-NBD, while the peptide signal is restricted to narrow areas (arrows). (B) In some neurons, gh625-NBD 
colocalizes with anti-tubulin III near the perikaryon. Other cytotypes are also labeled for gh625-NBD (arrow head). (C) DaPI staining of neuron nuclei. (D) Neurons 
immunoreactive for anti-tubulin III (magenta: false color) in the perikaryon and axons. (E) The same field in the fluorescein isothiocyanate channel shows the same neuron 
in (D) which is strongly labeled for gh625-NBD. (F) nMDP distribution colocalization color map of overlapping (D) and (E); the image clearly shows that gh625-NBD 
colocalizes with anti-tubulin III in the perikaryon and the axon emergence, exclusively. (G) Merged image of the aforementioned three channels, ie, DaPI, alexaFluor594, and 
fluorescein isothiocyanate. Scale bar: 50 µm for (A, B) and 10 µm for (C–G). 
Abbreviations: NBD, 7-nitrobenz-2-oxa-1,3-diazole-4-yl; DaPI, 4,6-diamidino-2-phenylindole; nMDP, normalized mean deviation product.
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Figure 10 Pixel count and pixel correlation analysis on images from control and gh625 NBD treated experimental groups.
Notes: Distribution of nMDP shows the degree of colocalization in the control, ie, vehicle or gh625 without NBD (solid lines) and gh625/anti-BBB (dashed lines) (A). The 
index of correlation histogram comparing control and gh625/anti-BBB images shows a high fraction of positively correlated pixels (B). Distribution of nMDP shows the 
degree of colocalization between the control (solid lines) and gh625/anti-gFaP (dashed lines) (C). The index of correlation comparison between control and gh625/anti-
gFaP showing a low fraction of positively correlated pixels in the images (D). 
Abbreviations: BBB, blood–brain barrier; GFAP, glial fibrillary acidic protein; NBD, 7-nitrobenz-2-oxa-1,3-diazole-4-yl; nMDP, normalized mean deviation product.
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Figure 11 effect of in vivo administration of gh625 on mitochondrial respiration and cytochrome oxidase activity detected in brain (A, C) and liver (B, D) homogenates in 
the rat. Values represent the mean ± standard error of three homogenate preparations from different rats.
Notes: each experiment was performed in triplicate. control rats received vehicle. 
Abbreviations: aDP, adenosine diphosphate; NBD, 7-nitrobenz-2-oxa-1,3-diazole-4-yl; rcr, respiratory control ratio.
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opening of the BBB.35 Here, we report early results showing 
that a membranotropic peptide derived from herpes virus type 
1 could be used as a potential delivery system for macromol-
ecules in vivo. These results, coupled with previous in vitro 
data, support the view that gH625 enters the BBB without 
involving endocytic processes. Hence, the eventual cargo 
may be immediately and completely available.
The gH625 peptide has a significant ability to penetrate 
brain cells. This was confirmed by both in vitro exposure of 
neuron and astrocyte cell lines to gH625 and in vivo admin-
istration of the peptide in rats. In vitro studies showed that 
both SH-SY5Y and U-87 mG cells can actually take up more 
than 90% of administered gH625, indicating that internal-
ization of gH625 into these cell lines is an efficient process. 
Uptake of the peptide was not associated with variation in 
cell viability or with alteration in maximal mitochondrial 
oxidative capacity, indicating that, at the dose tested, the 
peptide was devoid of cytotoxic effects. These data suggest 
that gH625 could potentially be used as a brain delivery 
system for macromolecules.
The results of in vivo administration of gH625 strongly 
support this possibility. Indeed, we demonstrated that, despite 
the blood filtration action of the liver, carried out through 
the gH625 uptake of Kupffer cells, gH625 substantially 
reaches the brain BBB vessels. Interestingly, gH625 could 
be found in the BBB endothelium, so this peptide can be 
efficiently accumulated in endothelial cells of the BBB. We 
also evaluated whether gH625 had actually crossed the BBB 
or was simply trapped within endothelial cells of the brain. 
In particular, although we did not detect any association with 
astrocytes, we were able to find the presence of gH625 in 
neurons. These data suggest that gH625 reaches the corti-
cal perikarya and their processes, demonstrating that this 
peptide may be useful in the development of functionalized 
nanosystems for drug delivery to the brain.
We also evaluated the ability of gH625 to affect mito-
chondrial oxidative capacity in terms of the mitochondrial 
respiration rate and/or cytochrome oxidase activity (the 
latter being an index of the maximal oxidative capacity of 
a cell or tissue), in view of the fundamental role played by 
the mitochondria in the energy metabolism of the cell. The 
results of this study indicate that administration of gH625 to 
rats does not influence the mitochondrial respiration rate or 
maximal oxidative capacity in brain and liver homogenates, 
suggesting that this peptide does not influence processes 
critical to cell survival.
The presence of multiple metabolic barriers may restrict 
the application of such a peptide-based ligand for targeted 
drug delivery in vivo. Peptides alone or conjugated on the 
surface of nanocarriers are subject to proteolysis in the blood 
after systemic administration. In addition, the BBB is also a 
metabolic barrier due to the presence of various enzymes in 
brain capillary endothelial cells. In our study, gH625 started 
to be degraded after 1 hour of incubation, but the intact pep-
tide was still present after 3.5 hours of incubation, and thus 
it has potential for extending brain targeting efficiency due 
to its resistance to proteolysis for 3.5 hours.
Due to its stability and targeting efficacy, we envisage 
that gH625 may be a promising candidate for designing a 
targeted delivery system. The exact molecular mechanism 
for the entry of gH625 remains to be established. However, 
the fact that it is a membranotropic peptide able to interact 
with the membrane bilayer and destabilize it locally and 
temporarily, suggests translocation across the membrane 
bilayer that does not seem to involve classical endocytosis 
mechanisms as previously demonstrated by inhibition of 
endocytosis in live cells.19
Our results show that gH625 may be used for mediating 
delivery to virtually any tissue and in particular across the 
BBB. gH625 could transport a wide variety of cargoes with 
intact bioactivity into almost any tissue or organ. Nonselec-
tive transduction is not a drawback because specific targeting 
units may be added to increase retention in specific tissues.
Conclusion
These results show for the first time that a membranotropic 
peptide can be incorporated in vitro by neuron or astrocyte 
cells and has the ability in vivo to accumulate in the brain 
and could be advantageously used as a new brain delivery 
system. Further work is underway with various therapeutic 
targets, including small molecules, macromolecules, and 
other pharmaceutical agents.
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